Sponsor Directory

Novartis Pharmaceuticals clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1758

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Interventions: dabrafenib, trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 4
States / cities: Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Pelacarsen (TQJ230); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 83
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: JSB462, Abiraterone, Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 21
States / cities: La Jolla, California • Santa Monica, California • Denver, Colorado + 18 more

Conditions: Systemic Lupus Erythematosus
Interventions: ianalumab, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 15
States / cities: Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Miami, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more

Conditions: IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Juvenile Psoriatic Arthritis
Interventions: Secukinumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 8 more

Conditions: Sjögren's Disease
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Sjögren´s Disease
Interventions: VAY736, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 20
States / cities: Peoria, Arizona • Clearwater, Florida • Tampa, Florida + 17 more

Conditions: Non-segmental Vitiligo
Interventions: GIA632, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 21 more

Conditions: Chronic Myeloid Leukemia
Interventions: Asciminib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: FWY003, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Huntington Beach, California • Sacramento, California • Santa Barbara, California + 11 more

About this Novartis Pharmaceuticals sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Novartis Pharmaceuticals is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Novartis Pharmaceuticals trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Novartis Pharmaceuticals clinical trials

Filter and sort this sponsor

Live official records

Dabrafenib and/or Trametinib Rollover Study

Pelacarsen Roll-over Extension Program

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

About this Novartis Pharmaceuticals sponsor directory page